As its full safety profile remains under investigation, the following reflects current available data and known class effects: Gastrointestinal symptoms are the most common: nausea, vomiting, diarrhoea, and constipation, particularly during dose escalation
As obesity, insulin resistance, and metabolic syndrome become more common in urban populations, advanced peptide therapies are gaining attention among doctors and metabolic health specialists
Age and sex also influenced results with younger participants and women reaching their plateau later
2010) Janssen Pharmaceutica Animal Health (acq
If youre still early in your treatment or havent increased your dose yet, be patientslow or nonexistent weight loss is common at first
doi:10.1177/00185787221125724 Karagiannis T, Avgerinos I, Liakos A, et al